Buchumschlag

Editorial: Disordered eating and irritable bowel syndrome—Do maladaptive eating and weight control behaviours increase risk of a maladaptive gut?

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Andrea Shin
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: Results from the Growing Up Today Study (GUTS)
von: Keming Yang, et al.
Veröffentlicht: (2024)

Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Letter: Irritable bowel syndrome and antibiotics
von: George F. Longstreth
Veröffentlicht: (2024)

Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study
von: Carl Eriksson, et al.
Veröffentlicht: (2024)

Editorial: Disorders of gut‐brain interaction—Don't forget the older person
von: Christopher J. Black
Veröffentlicht: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
von: Kyle Staller, et al.
Veröffentlicht: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability?
von: Joshua Reid, et al.
Veröffentlicht: (2024)

Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
von: Christy Riggott, et al.
Veröffentlicht: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply
von: Jessica A. Fitzpatrick, et al.
Veröffentlicht: (2024)

Editorial: GLP‐1 receptor agonists in inflammatory bowel disease—Is it time?
von: Konstantinos Arvanitakis, et al.
Veröffentlicht: (2024)

Editorial: Treatments for inflammatory bowel disease across the age‐spectrum—Are they the same?
von: Agnes Hiu Yan Ho, et al.
Veröffentlicht: (2024)

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
von: Abhinav Vasudevan, et al.
Veröffentlicht: (2024)

The contribution of dietary advanced glycation end‐products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study
von: Fangyuan Jiang, et al.
Veröffentlicht: (2024)

Inflammatory bowel disease in 2024 and beyond
von: Richard B. Gearry, et al.
Veröffentlicht: (2024)

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
von: Ayesha Shah, et al.
Veröffentlicht: (2024)

Terlipressin therapy is associated with increased risk of colonisation with multidrug‐resistant bacteria in patients with decompensated cirrhosis
von: Marcus M. Mücke, et al.
Veröffentlicht: (2024)

Paediatric‐onset immune‐mediated inflammatory disease is associated with an increased mortality risk—A nationwide study
von: Mikkel Malham, et al.
Veröffentlicht: (2024)

Review article: Prevention of inflammatory bowel disease—The path forward
von: Sérgio Bronze, et al.
Veröffentlicht: (2024)

Performance of bowel preparation quality scales in patients with Crohn's disease
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
von: Nurulamin M. Noor, et al.
Veröffentlicht: (2024)

Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
von: Tsz Hong Yiu, et al.
Veröffentlicht: (2024)

Review article: Evidence‐based dietary management of inflammatory bowel disease
von: Peter R. Gibson, et al.
Veröffentlicht: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
von: Abhinav Vasudevan, et al.
Veröffentlicht: (2024)

Letter: Allostatic load—A potential key in the development of inflammatory bowel disease
von: Maryam Kharal, et al.
Veröffentlicht: (2024)

Clinical trial: The effectiveness of long‐acting somatostatin analogue for output reduction of high‐output intestinal fistula or small bowel enterostomy. A randomised controlled trial
von: Allard S. Timmer, et al.
Veröffentlicht: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
von: Eiichi Ogawa
Veröffentlicht: (2024)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
von: Amanda Ricciuto, et al.
Veröffentlicht: (2024)

Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
von: Thanaboon Chaemsupaphan, et al.
Veröffentlicht: (2024)

Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
von: Léa Sequier, et al.
Veröffentlicht: (2024)

Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound
von: Cathy Lu, et al.
Veröffentlicht: (2024)

Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission
von: Arta Aliu, et al.
Veröffentlicht: (2024)

Letter: Light in the lumen—The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease
von: R. M. Mathias, et al.
Veröffentlicht: (2024)

Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies
von: Iris Barth, et al.
Veröffentlicht: (2024)

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon
von: D. Bogatic, et al.
Veröffentlicht: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
von: Yewan Park, et al.
Veröffentlicht: (2024)

Editorial: Resecting Assumptions—Do Proctocolectomy Guidelines Hold Up? Author's Reply
von: Erik Lundqvist, et al.
Veröffentlicht: (2025)

Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes
von: Xianhua Mao, et al.
Veröffentlicht: (2024)

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
von: Aakash Desai, et al.
Veröffentlicht: (2024)

Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018
von: Rie Louise Møller Nordestgaard, et al.
Veröffentlicht: (2024)

Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
von: Lana Bridi, et al.
Veröffentlicht: (2024)